ANRIL has been found to be up-regulated in leukemia, prostate cancer, basal cell carcinoma and glioma, whereas depletion of ANRIL has been implicated in reduced proliferation, indicating its role in cancerogenesis [51-53]. The gene discussed is CDKN2B-AS1; the disease is Familial prostate cancer.